Multidrug resistance in relapsed acute myeloid leukemia: Evidence of biological heterogeneity-Reference-Cited by-同舟云学术

Multidrug resistance in relapsed acute myeloid leukemia: Evidence of biological heterogeneity

Published:2013-05-14 Issue:16 Volume:119 Page:3076-3083
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Patel Chirayu¹²,Stenke Leif³⁴,Varma Sudhir⁵,Lindberg Marita Lagergren³⁴,Björkholm Magnus³,Sjöberg Jan⁴,Viktorsson Kristina⁴,Lewensohn Rolf⁴,Landgren Ola⁶,Gottesman Michael M.¹,Gillet Jean-Pierre¹

Affiliation:

1. Laboratory of Cell Biology; National Cancer Institute; National Institutes of Health; Bethesda Maryland

2. Howard Hughes Medical Institute (HHMI)-National Institutes of Health (NIH) Research Scholars Program; Bethesda Maryland

3. Department of Medicine; Karolinska Institutet and University Hospital; Stockholm Sweden

4. Department of Oncology-Pathology; Karolinska Institutet and University Hospital; Stockholm Sweden

5. Bioinformatics and Computational Biosciences Branch; Office of Cyber Infrastructure and Computational Biology, Office of Science Management and Operations, National Institute of Allergy and Infectious Diseases, NIH; Bethesda Maryland

6. Metabolism Branch, NCI, NIH; Bethesda Maryland

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.28098/fullpdf

Reference24 articles.

1. Acute myelogenous leukemia;Shipley;Exp Hematol,2009

2. Clonal architecture of secondary acute myeloid leukemia;Walter;N Engl J Med,2012

3. ABC drug transporters as molecular targets for the prevention of multidrug resistance and drug-drug interactions;Calcagno;Curr Drug Deliv,2007

4. Multidrug resistance in leukemia;Leith;Curr Opin Hematol,1998

5. MDR1/P-GP expression as a prognostic factor in acute leukemias;Marie;Adv Exp Med Biol,1999

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. WT1 Expression Is Associated with Poor Overall Survival after Azacytidine and DLI in a Cohort of Adult AML and MDS Patients;Cancers;2024-09-04

2. Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts;Blood Cancer Discovery;2024-05-01

3. A new insight updates in diagnosis and management of acute lymphoblastic leukemia, cytogenetics, immunophenotyping, and proteomic profile;Electronic Journal of General Medicine;2023-09-01

4. Isocitrate dehydrogenase 2 inhibitor enasidenib synergizes daunorubicin cytotoxicity by targeting aldo-keto reductase 1C3 and ATP-binding cassette transporters;Archives of Toxicology;2022-08-16

5. Evaluation of Protoprimulagenin A and Bonediol Isolated from Bonellia macrocarpa in Myeloid Leukemia Cell Lines;Revista Brasileira de Farmacognosia;2022-06-28